An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'

AstraZeneca and Bristol Myers in merger talks to create a cancer-drug giant; AstraZeneca shares fall 8%. Analysts find it odd—signals possible AstraZeneca pipeline weakness after drug failure; Bristol Myers has key pending readouts; deal risks antitrust review and patent cliffs.